Table 1.
Baseline (1999-2000) characteristics of the MPS study population, the Study of Women’s Health Across the Nation (N = 1371).
| Characteristics | Statistics |
|---|---|
| PFAS (ng/mL), median (Q1, Q3) | |
| n-PFOA | 4.1 (2.9, 5.8) |
| PFNA | 0.6 (0.4, 0.8) |
| PFHxS | 1.5 (1.0, 2.4) |
| n-PFOS | 17.5 (12.5, 24.9) |
| Sm-PFOS | 7.3 (4.7, 11.0) |
| Total PFOS | 24.9 (17.6, 35.8) |
| MeFOSAA | 1.5 (0.9, 2.3) |
| EtFOSAA | 1.2 (0.7, 2.2) |
| Sex hormone, median (Q1, Q3)a | |
| FSH, IU/L | 34.1 (14.8, 84.8) |
| E2, pg/mL | 30.0 (17.5, 67.3) |
| Testosterone, ng/dL | 33.6 (23.8, 46.9) |
| SHBG, nM | 38.7 (25.4, 54.3) |
| Covariate, mean ± SD or n (%) | |
| Age, year | 49.5 ± 2.6 |
| Body mass index, kg/m2 | 28.0 ± 7.4 |
| Site | |
| Southeast Michigan, USA | 254 (18.5) |
| Boston, MA, USA | 231 (16.9) |
| Oakland, CA, USA | 303 (22.1) |
| Los Angeles, CA, USA | 356 (26.0) |
| Pittsburgh, PA, USA | 227 (16.6) |
| Race/ethnicity | |
| White | 683 (49.8) |
| Black | 304 (22.2) |
| Chinese | 177 (12.9) |
| Japanese | 207 (15.1) |
| Education | |
| Some high school | 41 (3.0) |
| High school | 208 (15.2) |
| Some college | 439 (32.2) |
| College | 334 (24.5) |
| Postcollege | 342 (25.1) |
| Smoking status | |
| Never | 864 (63.0) |
| Former | 364 (26.6) |
| Current | 143 (10.4) |
| Secondhand smoking exposure | |
| None | 816 (59.5) |
| Any | 555 (40.5) |
| Parity | |
| Nulliparous | 265 (19.3) |
| 1-2 | 713 (52.0) |
| ≥3 | 393 (28.7) |
| Menopausal statusb | |
| Pre or early peri | 924 (67.4) |
| Late peri or post (natural and surgical) | 447 (32.6) |
Abbreviations: E2, estradiol; EtFOSAA, 2-(N-ethyl-perfluorooctane sulfonamido) acetate FSH, follicle-stimulating hormone; MeFOSAA, 2-(N-methyl-perfluorooctane sulfonamido) acetate; n-PFOA, linear perfluorooctanoate; n-PFOS, linear perfluorooctane sulfonate; PFAS, per- and polyfluoroalkyl substances; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoate; SHBG, sex hormone-binding globulin; Sm-PFOS, sum of perfluoromethylheptane sulfonate isomers.
a Measure taken from first visit not using hormone therapy.
b Menopausal status from first visit not using hormone therapy.